Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
life sciences
novartis
6
×
boston blog main
national blog main
national top stories
boston top stories
new york top stories
san francisco top stories
amgen
cancer
clinical trials
europe top stories
indiana blog main
indiana top stories
national
new york blog main
roche
san francisco blog main
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
cancer drugs
deals
detroit blog main
detroit top stories
diagnostics
drug pricing
eli lilly
europe blog main
fda
gene therapy
genentech
hepatitis b
life science
merck
microbiome
pfizer
purdue pharma
What
drug
6
×
fda
new
bio
brings
medicines
patients
pricing
roundup
sciences
therapy
acquire
acquisitions
address
advantages
agreed
approval
approved
approves
atrophy
bar
biggest
billion
biotech
blueprint
build
buy
cancer
carries
cash
ceo
certain
cholesterol
company
company’s
compound
daily
daniel
deal
debut
Language
unset
6
×
Current search:
drug
×
biotech
×
novartis
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone